GlassScriptPhysician profile
Praneet Korrapati
NPI 1467895748
$8,123.57
in general payments reported to CMS, 2019-2025
29 companies · $1,502 in 2025
The $1,502 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $570 · 2020: $550 · 2021: $790 · 2022: $1,092 · 2023: $2,253 · 2024: $1,368 · 2025: $1,502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,080 · Education: $42.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,080.47 |
| Education | $42.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,018.47 | 2019-2025 | |
| Boston Scientific Corporation | $799.13 | 2021-2025 | Axios, Exalt Model D, General - Hemostasis |
| Takeda Pharmaceuticals U.S.A., INC. | $645.51 | 2019-2025 | Entyvio, Gattex |
| Pfizer INC. | $588.47 | 2019-2025 | |
| Gilead Sciences, INC. | $467.08 | 2019-2025 | |
| Erbe USA INC | $285.32 | 2023 | Erbe Apc |
| Janssen Biotech, INC. | $268.44 | 2019-2025 | Tremfya, Stelara |
| Intercept Pharmaceuticals, INC. | $247.37 | 2020-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $209.44 | 2019-2024 | Dificid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $207.13 | 2020-2025 | Trulance, Xifaxan, Relistor |
| Regeneron Healthcare Solutions, INC. | $192.65 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $160.52 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $158.72 | 2022-2025 | Sucraid, Sucraid |
| Nestle Healthcare Nutrition INC. | $157.20 | 2021-2023 | |
| Braintree Laboratories, INC. | $128.65 | 2020-2023 | Sutab, Suflave |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $100.36 | 2024-2025 | Zenpep |
| Genzyme Corporation | $99.92 | 2022-2025 | |
| Lilly USA, LLC | $79.57 | 2024-2025 | Omvoh, Zepbound |
| Celgene Corporation | $55.47 | 2022-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $53.37 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $48.47 | 2025 | Rezdiffra |
| Celltrion USA INC. | $39.36 | 2025 | Vegzelma |
| Phadia US INC. | $19.68 | 2025 | Immunocap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.42 | 2023 | Cyltezo |
| Vivus LLC | $16.27 | 2024 | Qsymia |
| Capsovision, INC. | $15.90 | 2023 | Capsocam Plus |
| Mallinckrodt Hospital Products INC. | $15.57 | 2025 | Terlivaz |
| Exact Sciences Corporation | $14.31 | 2023 | Cologuard Collection Kit |
| Dova Pharmaceuticals | $12.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Praneet Korrapati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.